Skip to the answer

Dextroamphetamine

Dextroamphetamine is a central nervous system (CNS) stimulant used to treat attention deficit hyperactivity disorder (ADHD) and, in some oral products, narcolepsy.

Brand names DexedrineDexampexDextroStatFerndexLiquADD +4 more
Drug classes Central Nervous System Stimulant
Rx Schedule CII Forms 5
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 27 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 4, 2026 🚨Recall on record
Dextroamphetamine at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Dextroamphetamine is a stimulant for ADHD and, in some oral forms, narcolepsy (sudden, uncontrollable sleepiness), that blocks the recycling of dopamine and norepinephrine and boosts their release, an older, well-known option on the U.S. market since about 1976 and available generically. Most people tolerate it reasonably well, and a smaller appetite and trouble sleeping are what people notice most. Respect its boxed warning for abuse, misuse and addiction, which can lead to overdose and death, so lock it up and never share it. Keep up with follow-up visits, since it can raise blood pressure and heart rate, stir up mood changes and slow growth in children.

Clinical pearls

  • Vitamin C and fruit juice can weaken it, while sodium bicarbonate antacids can strengthen it, so space them away from doses.
  • Take the last dose early in the day, because late-evening doses commonly cause trouble sleeping.
  • Tell every prescriber you take it, since MAOIs, linezolid, tramadol, triptans and many antidepressants can interact dangerously.
  • With the Xelstrym patch, keep heating pads, electric blankets and hair dryers away, because heat increases how much drug is absorbed.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Xelstrym has a high potential for abuse and misuse, which can lead to addiction, overdose and death. The risk is higher with larger doses or unapproved use, such as snorting or injecting.

Your prescriber should check your risk before starting and keep monitoring you. Store it safely, preferably locked, never share it, and dispose of unused medicine properly. Watch for signs of misuse or addiction.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asTablet, Extended-release capsule, Oral solution +2
Earliest FDA record1955
Companies listing it with the FDA17
FDA label last updatedMay 19, 2025
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Dextroamphetamine, written from its FDA label.

What Dextroamphetamine is used for

▾

Dextroamphetamine is used for the following, depending on the product:

  • Narcolepsy: Dexedrine, dextroamphetamine extended-release capsules, Zenzedi and other dextroamphetamine tablets, and the oral solutions including Procentra.
  • ADHD in ages 6 to 16: Dexedrine and dextroamphetamine extended-release capsules, as part of a total treatment program.
  • ADHD in children ages 3 to 16: Zenzedi, dextroamphetamine tablets and the oral solutions including Procentra.
  • ADHD in adults and children 6 and older: Xelstrym skin patch.

How Dextroamphetamine works

▾

Dextroamphetamine is a CNS stimulant. It blocks the re-uptake of norepinephrine and dopamine into nerve cells and increases their release. The exact way it helps ADHD is not known.

Dextroamphetamine dosage

▾

Dextroamphetamine is taken by mouth as a capsule, tablet or liquid, or applied to the skin as the Xelstrym patch. Your prescriber chooses the lowest effective dose and adjusts it over time.

  • Avoid late-evening doses because of insomnia.
  • For narcolepsy with oral products, the first dose is given on waking, with 1 or 2 more doses 4 to 6 hours apart.
  • Xelstrym goes on 2 hours before the effect is needed and comes off within 9 hours, rotating sites.

Follow your prescriber and product label.

Dosing details from the FDA-approved label

From the Dextroamphetamine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Narcolepsy (tablets/oral solution), usual dose
    • Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response
    • Give first dose on awakening
    • Additional doses (1 or 2) at intervals of 4 to 6 hours
    • Dosage should be reduced if bothersome adverse reactions appear (e.g., insomnia or anorexia)
  • Narcolepsy, patients aged 6 to 12
    • Start with 5 mg daily
    • Daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained
    • Narcolepsy seldom occurs in children under 12 years of age
  • Narcolepsy, patients 12 years of age and older
    • Start with 10 mg daily
    • Daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained
  • Attention Deficit Disorder with Hyperactivity, pediatric patients 3 to 5 years of age
    • Start with 2.5 mg daily
    • Daily dosage may be raised in increments of 2.5 mg at weekly intervals until an optimal response is obtained
    • Not recommended for pediatric patients under 3 years of age
  • Attention Deficit Disorder with Hyperactivity, pediatric patients 6 years of age and older
    • Start with 5 mg once or twice daily
    • Daily dosage may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained
    • Give first dose on awakening
    • Additional doses (1 or 2) at intervals of 4 to 6 hours
    • Maximum: Only in rare cases will it be necessary to exceed a total of 40 mg per day
  • Xelstrym transdermal system, pediatric patients 6 to 17 years
    • Starting dose is 4.5 mg/9 hours
    • May be adjusted in weekly increments of 4.5 mg
    • Apply 2 hours before an effect is needed and remove within 9 hours
    • Maximum: 18 mg/9 hours
  • Xelstrym transdermal system, adults
    • Starting dose is 9 mg/9 hours
    • May be adjusted
    • Apply 2 hours before an effect is needed and remove within 9 hours
    • Maximum: 18 mg/9 hours
  • Xelstrym, severe renal impairment (GFR 15 to < 30 mL/min/1.73 m2)
    • Maximum dose should not exceed 13.5 mg/9 hours
    • Maximum: 13.5 mg/9 hours
    • Severe renal impairment
  • Xelstrym, end stage renal disease (GFR < 15 mL/min/1.73 m2)
    • Maximum recommended dose is 9 mg/9 hours
    • Maximum: 9 mg/9 hours
    • End stage renal disease
Read the label’s full dosing text

DOSAGE AND ADMINISTRATION Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of the resulting insomnia. Narcolepsy Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate tablets may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours. Attention Deficit Disorder with Hyperactivity Not recommended for pediatric patients under 3 years of age. In pediatric patients from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until an optimal response is obtained. In pediatric patients 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours. Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy. Prior to treating patients with dextroamphetamine sulfate tablets assess: for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) ( see WARNINGS ). the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome ( see WARNINGS ).

Read the full Dosage and Administration section on DailyMed →

Dextroamphetamine side effects

▾

Common side effects include:

Common side effects

  • Decreased appetite
  • Trouble sleeping (insomnia)
  • Headache
  • Stomach pain, nausea or vomiting
  • Irritability or mood swings
  • Tics
  • Faster heart rate and higher blood pressure
  • Skin pain, itching or redness at the patch site (Xelstrym)
  • Skin irritation or itching at the Xelstrym patch site

When to get medical help

  • Get help right away for chest pain, fainting or a racing or irregular heartbeat, especially if you have heart problems.
  • Call your doctor if you notice new hallucinations, paranoid or delusional thinking, or manic behavior.
  • Call your doctor if fingers or toes turn pale, blue, numb or painful, or develop sores.
  • Seek urgent care for signs of serotonin syndrome: agitation, hallucinations, fever, heavy sweating, tremor, stiff muscles, fast heartbeat, vomiting or diarrhea.
  • Tell your doctor about new or worsening tics or Tourette’s syndrome.
  • Contact your doctor if a child is not gaining weight or growing as expected.
  • With Xelstrym, stop it and call your doctor if skin redness comes with swelling, bumps or blisters that don’t improve within 48 hours or spread beyond the patch site.
  • Seek help for seizures, or for signs of misuse or addiction.

Call your doctor about heart symptoms, new mental changes, circulation changes in fingers or toes, slowed growth in children, or signs of serotonin syndrome.

Dextroamphetamine warnings and precautions

▾
  • Abuse, misuse and addiction can lead to overdose and death. Store it safely and never share it.
  • Heart risks: sudden death has been reported in people with serious heart disease. Blood pressure and heart rate can rise.
  • Mental health: it can worsen psychosis, trigger mania, or cause new psychotic symptoms.
  • Growth: weight loss and slowed growth can occur in children.
  • Other: seizures, Raynaud’s phenomenon, tics, and serotonin syndrome.
  • Xelstrym: skin allergy, application site reactions and increased absorption with heat.

Dextroamphetamine interactions

▾

Several drugs and substances can change how dextroamphetamine works or raise its risks:

  • MAO inhibitors: risk of dangerous high blood pressure.
  • Serotonergic drugs such as SSRIs, SNRIs, triptans, tramadol and St. John’s Wort: risk of serotonin syndrome.
  • CYP2D6 inhibitors such as paroxetine, fluoxetine, quinidine and ritonavir: can raise drug levels.
  • Vitamin C and fruit juices: can lower absorption.
  • Sodium bicarbonate, acetazolamide and some thiazides: can strengthen effects.
  • Blood pressure medicines: may be less effective.
  • Heat on the Xelstrym patch: more drug absorbed.

Interactions listed in the FDA-approved label

From the Dextroamphetamine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • MAO inhibitors (MAOI antidepressants, metabolite of furazolidone): They slow amphetamine metabolism, potentiating amphetamines, which can cause headaches and other signs of hypertensive crisis, neurological toxic effects and malignant hyperpyrexia, sometimes fatal.
  • Serotonergic drugs (SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort): Concomitant use increases the risk of serotonin syndrome. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome; if it occurs, discontinue dextroamphetamine and the serotonergic drug(s).
  • CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine, ritonavir): May increase dextroamphetamine exposure and increase the risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome; if it occurs, discontinue dextroamphetamine and the CYP2D6 inhibitor.
  • Acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, ammonium chloride, sodium acid phosphate): Gastrointestinal agents lower absorption and urinary agents increase urinary excretion of amphetamines; both lower blood levels and efficacy. Xelstrym label: adjust dosage based on clinical response.
  • Alkalinizing agents (sodium bicarbonate, acetazolamide, some thiazides): They increase absorption or decrease urinary excretion of amphetamines, increasing blood levels and potentiating their actions.
  • Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
  • Tricyclic antidepressants: Amphetamines may enhance the activity of tricyclics; d-amphetamine with desipramine or protriptyline causes striking and sustained increases in brain d-amphetamine concentration, and cardiovascular effects can be potentiated.
  • Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
  • Chlorpromazine and haloperidol: They block dopamine and norepinephrine reuptake, inhibiting the central stimulant effects of amphetamines.
  • Propoxyphene: In propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
Read the label’s full interactions text

Drug Interactions MAO Inhibitors - MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results. Serotonergic Drugs - The concomitant use of dextroamphetamine sulfate oral solution and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine sulfate oral solution initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine sulfate oral solution and the concomitant serotonergic drug(s) (see WARNINGS , PRECAUTIONS ) . Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort. CYP2D6 Inhibitors - The concomitant use of dextroamphetamine sulfate oral solution and CYP2D6 inhibitors may increase the exposure of dextroamphetamine sulfate oral solution compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during dextroamphetamine sulfate oral solution initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine sulfate oral solution and the CYP2D6 inhibitor (see WARNINGS , OVERDOSAGE ) . Examples of CYP2D6 Inhibitors include paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿129 supplements and herbs with documented Dextroamphetamine interactions, ranked by severity Check Dextroamphetamine against a supplement or herb →

Before taking Dextroamphetamine

▾
  • Heart disease or rhythm problems
  • Psychosis, bipolar disorder, depression or a family history of these
  • Seizures, tics or Tourette’s syndrome
  • Allergy to amphetamine products, or current MAOI use
  • Pregnancy: possible early delivery, low birth weight and newborn withdrawal symptoms
  • Breastfeeding: not recommended because it passes into milk
  • Children: growth should be monitored; age limits vary by product
  • Older adults: usually start with lower doses
  • Severe kidney disease: Xelstrym has lower maximum doses

Dextroamphetamine overdose

▾

Too much can cause a fast or irregular heartbeat, high or low blood pressure, agitation, confusion, hallucinations, seizures, dangerously high body temperature and muscle breakdown. Heart attack or sudden cardiac death can occur. Call Poison Help at 1-800-222-1222 or get emergency care. For Xelstrym, remove all patches right away and clean the skin, since absorption can continue after removal.

What Dextroamphetamine does in the body

▾

Amphetamines block the re-uptake of norepinephrine and dopamine into nerve cells. They also increase the release of these chemicals into the space around the cells. This produces the stimulant effect.

How your body processes Dextroamphetamine

▾

With the Xelstrym patch, blood levels typically peak 6 to 9 hours after application, and about 90% of the drug is delivered over 9 hours. Heat speeds absorption. After the patch is removed, the half-life is about 6.4 hours in children and 11.5 hours in adults.

The body breaks amphetamine down in the liver and clears it through the urine, and urine acidity affects how fast. Liver or kidney problems can prolong exposure.

How to store Dextroamphetamine

▾

Store at 20° to 25°C (68° to 77°F) . Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

129

Supplements & herbs that interact with Dextroamphetamine

129 supplements and herbal products have documented interactions with Dextroamphetamine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 6
  • Moderate · 100
  • Minor · 23
ACTIVATED CHARCOAL Major EPHEDRA Major LITHIUM Major PEYOTE Major RAUVOLFIA VOMITORIA Major SIDA CORDIFOLIA Major 1,3-DMAA Moderate 1,3-DMBA Moderate +121 more
Every supplement checked against Dextroamphetamine — ranked by severity The full interaction hub: 6 major · 100 moderate · 23 minor · every one linked to its full report. Check Dextroamphetamine against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Dextroamphetamine: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Dextroamphetamine — the kind of thing our pharmacy team would talk through with you at the counter.

What is dextroamphetamine for?

▾
It treats ADHD, and some oral forms are also used for narcolepsy. Which use and age range applies depends on the product you have. Your prescriber decides if it fits you or your child.

How should I take it?

▾
Take it exactly as prescribed, usually at the lowest dose that works. Avoid late-evening doses because they can keep you awake. If you use the Xelstrym patch, put it on about 2 hours before you need the effect and remove it within 9 hours.

What side effects should I expect?

▾
Common ones are reduced appetite, trouble sleeping, headache, stomach upset and irritability. Kids may lose weight, so we watch growth. Call your doctor for chest pain, a racing heartbeat, hallucinations, or color changes in your fingers or toes.

Can I take it with my other medicines?

▾
Check with me first. MAO inhibitors are a serious problem, and antidepressants, triptans, tramadol and St. John’s Wort can raise the risk of serotonin syndrome. Vitamin C and fruit juices can lower how well it works.

Is there a risk of addiction?

▾
Yes. Dextroamphetamine has a high potential for abuse and misuse, and misuse can cause overdose and death. Keep it locked up, never share it, and dispose of leftovers properly.

Is it safe in pregnancy or while breastfeeding?

▾
Use in pregnancy only if the benefit outweighs the risk, since babies may be born early or small or have withdrawal symptoms. It passes into breast milk, and breastfeeding is not recommended. Talk with your doctor if you are pregnant or planning to be.

Is Dextroamphetamine available over the counter?

▾
No. Dextroamphetamine is a prescription medicine: every Dextroamphetamine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

Is Dextroamphetamine a controlled substance?

▾
Yes — Dextroamphetamine is a federally controlled substance (Schedule II) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.

When was Dextroamphetamine first available?

▾
The earliest FDA record we hold for Dextroamphetamine is from 1955: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Dextroamphetamine was first used.

Who makes Dextroamphetamine?

▾
17 companies currently list Dextroamphetamine products in the FDA's NDC Directory, including Bryant Ranch Prepack, Azurity Pharmaceuticals, Inc., Winder Laboratories LLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Dextroamphetamine on HelloPharmacist

📊Dextroamphetamine supplement interactions129 checked — ranked by severity 🌿Drug & Supplement CheckerDextroamphetamine vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Dextroamphetamine NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Dextroamphetamine Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Dextroamphetamine forms and strengths (how it comes)

Dextroamphetamine is available in 5 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Zenzedi
How this form is used
What it may be used for
  • Zenzedi is used for narcolepsy.
  • Zenzedi is used for ADHD in children ages 3 to 16 as part of a total treatment program.
Important instructions
  • Zenzedi is taken by mouth at the lowest effective dose, individually adjusted.
  • Zenzedi late-evening doses should be avoided because of insomnia.
  • For narcolepsy, Zenzedi’s first dose is given on waking, with 1 or 2 more doses 4 to 6 hours apart.
Available strengths 7 strengths
2.5 mg 5 mg 7.5 mg 10 mg 15 mg 20 mg
Show 1 more strength Show fewer strengths
30 mg
111 FDA-listed product records ⓘ

Extended-release capsule

By mouth
Brands Dexedrine
How this form is used
What it may be used for
  • Dexedrine is used for narcolepsy.
  • Dexedrine is used for ADHD in ages 6 to 16 as part of a total treatment program.
Important instructions
  • Dexedrine is taken by mouth at the lowest effective dose, individually adjusted.
  • Dexedrine late-evening doses should be avoided because of insomnia.
  • Before starting Dexedrine, your prescriber checks for heart disease and for tics or Tourette’s syndrome.
Available strengths 3 strengths
5 mg 10 mg 15 mg
31 FDA-listed product records ⓘ

Oral solution

By mouth
Brands Procentra
How this form is used
What it may be used for
  • Procentra is used for narcolepsy.
  • Procentra is used for ADHD in children ages 3 to 16 as part of a total treatment program.
Important instructions
  • Procentra is taken by mouth at the lowest effective dose, individually adjusted.
  • Procentra late-evening doses should be avoided because of insomnia.
  • For narcolepsy, Procentra’s first dose is given on waking, with 1 or 2 more doses 4 to 6 hours apart.
Available strengths 2 strengths
5 mg/5 mL 1 kg/kg
13 FDA-listed product records ⓘ

Skin patch

Through the skin
Brands Xelstrym
How this form is used
What it may be used for
  • Xelstrym is used for ADHD in adults and children 6 years and older.
Important instructions
  • Xelstrym is applied about 2 hours before an effect is needed and removed within 9 hours.
  • Xelstrym goes on the hip, upper arm, chest, upper back or flank, and the site changes with each new patch.
  • Avoid heat such as heating pads or hair dryers on Xelstrym.
  • Xelstrym should not be swapped for other amphetamine products milligram for milligram.
Available strengths 4 strengths
4.5 mg 9 mg 13.5 mg 18 mg
8 FDA-listed product records ⓘ

Capsule

By mouth
Available strengths 1 strength
10 mg
1 FDA-listed product record ⓘ

Dextroamphetamine on the U.S. market: products, makers and brands

How Dextroamphetamine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

17 companies list 62 Dextroamphetamine product records with the FDA, mostly as tablet, extended-release capsule, oral solution; the earliest marketing or approval year on record is 1955. Brand names on the directory include Dexedrine, Dexampex, DextroStat and 6 more; the rest are generics.

5
Dose forms ⓘ
17
Labelers (makers, repackagers, distributors)
8
Brand names
62
FDA-listed product records ⓘ
1955
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (14) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Bryant Ranch Prepack16%
Azurity Pharmaceuticals, Inc.11%
Winder Laboratories LLC11%
SpecGx LLC8%
Wilshire Pharmaceuticals, Inc.8%
Noven Therapeutics, LLC6%
Other makers39%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Dextroamphetamine is used (Medicaid data)

A general measure of how commonly Dextroamphetamine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Dextroamphetamine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

132,973
Medicaid prescriptions filled (Q1–Q4 2025)
$15.4M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Dextroamphetamine prescribed? Of the 1,601 medications we measure, Dextroamphetamine ranks #467 by Medicaid prescriptions — more than 71% of them.

Where Dextroamphetamine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #467 of 1,601
#462 Ranolazine 134,744 Rx #463 Dextromethorphan and B... 134,150 Rx #464 Desonide Topical 133,862 Rx #465 Desonide 133,862 Rx #466 Liothyronine 133,453 Rx #467 Dextroamphetamine 132,973 Rx #468 Epinephrine / Lidocain... 132,083 Rx #469 Tranexamic Acid 131,595 Rx #470 Olanzapine / Samidorph... 130,976 Rx #471 Bisoprolol 130,591 Rx #472 Miconazole 130,151 Rx

Utilization by Dextroamphetamine product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 10 mg oral tablet is the most-dispensed Dextroamphetamine product — about 29% of these Medicaid prescriptions.

dextroamphetamine sulfate 10 MG Oral Tablet Most dispensed

38,949 Medicaid prescriptions (Q1–Q4 2025) 29% of Dextroamphetamine prescriptions shown $1.6M gross reimbursement (before rebates) ≈ $42 per prescription (gross)

Summed across the 7 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884385

dextroamphetamine sulfate 15 MG Extended Release Oral Capsule

21,275 Medicaid prescriptions (Q1–Q4 2025) 16% of Dextroamphetamine prescriptions shown $1.7M gross reimbursement (before rebates) ≈ $80 per prescription (gross)

Summed across the 2 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884532

dextroamphetamine sulfate 5 MG Oral Tablet

19,570 Medicaid prescriptions (Q1–Q4 2025) 15% of Dextroamphetamine prescriptions shown $653,869 gross reimbursement (before rebates) ≈ $33 per prescription (gross)

Summed across the 6 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884386

dextroamphetamine sulfate 10 MG Extended Release Oral Capsule

18,775 Medicaid prescriptions (Q1–Q4 2025) 14% of Dextroamphetamine prescriptions shown $1.2M gross reimbursement (before rebates) ≈ $65 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884520

dextroamphetamine sulfate 1 MG/ML Oral Solution

17,068 Medicaid prescriptions (Q1–Q4 2025) 13% of Dextroamphetamine prescriptions shown $5.9M gross reimbursement (before rebates) ≈ $345 per prescription (gross)

Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884522

dextroamphetamine sulfate 20 MG Oral Tablet

4,581 Medicaid prescriptions (Q1–Q4 2025) 3% of Dextroamphetamine prescriptions shown $1.2M gross reimbursement (before rebates) ≈ $260 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1535454

dextroamphetamine sulfate 5 MG Extended Release Oral Capsule

4,304 Medicaid prescriptions (Q1–Q4 2025) 3% of Dextroamphetamine prescriptions shown $201,102 gross reimbursement (before rebates) ≈ $47 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884535

dextroamphetamine sulfate 15 MG Oral Tablet

2,278 Medicaid prescriptions (Q1–Q4 2025) 2% of Dextroamphetamine prescriptions shown $536,327 gross reimbursement (before rebates) ≈ $235 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884684

dextroamphetamine sulfate 30 MG Oral Tablet

1,970 Medicaid prescriptions (Q1–Q4 2025) 1% of Dextroamphetamine prescriptions shown $463,240 gross reimbursement (before rebates) ≈ $235 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1535470

9 HR dextroamphetamine 1 MG/HR Transdermal System

1,370 Medicaid prescriptions (Q1–Q4 2025) 1% of Dextroamphetamine prescriptions shown $680,152 gross reimbursement (before rebates) ≈ $496 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2624732

9 HR dextroamphetamine 0.5 MG/HR Transdermal System

792 Medicaid prescriptions (Q1–Q4 2025) <1% of Dextroamphetamine prescriptions shown $384,462 gross reimbursement (before rebates) ≈ $485 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2624726

9 HR dextroamphetamine 2 MG/HR Transdermal System

791 Medicaid prescriptions (Q1–Q4 2025) <1% of Dextroamphetamine prescriptions shown $394,272 gross reimbursement (before rebates) ≈ $498 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2624712

9 HR dextroamphetamine 1.5 MG/HR Transdermal System

785 Medicaid prescriptions (Q1–Q4 2025) <1% of Dextroamphetamine prescriptions shown $387,318 gross reimbursement (before rebates) ≈ $493 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2624701

dextroamphetamine sulfate 2.5 MG Oral Tablet

339 Medicaid prescriptions (Q1–Q4 2025) <1% of Dextroamphetamine prescriptions shown $70,062 gross reimbursement (before rebates) ≈ $207 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1425847

dextroamphetamine sulfate 7.5 MG Oral Tablet

126 Medicaid prescriptions (Q1–Q4 2025) <1% of Dextroamphetamine prescriptions shown $32,927 gross reimbursement (before rebates) ≈ $261 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1425854

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Dextroamphetamine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 37 of 109 listed Dextroamphetamine NDCs with Medicaid activity.

Compare Dextroamphetamine products

A representative set of FDA-listed product records for Dextroamphetamine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 62 of 62 products — FDA National Drug Code Directory. See every product, package size and price: browse all 62 Dextroamphetamine NDCs →

Dextroamphetamine recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 2 Dextroamphetamine recalls since July 2021. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class II Oct 31, 2024 · Noven Pharmaceuticals Inc
Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).
  • Xelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 hours, 30 individually sealed transdermal patches, inside a foil-sealed polypropylene tray, packed in a paper carton/box,… Lots: Lot # 95598, Exp 02/28/25 FDA record D-0055-2025 →
Class I Jan 4, 2024 · Terminated · Azurity Pharmaceuticals, Inc.
Labeling: Label Mix-up
  • Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only, Mfd. for: Arbor Pharmaceuticals, LLC., Atlanta, Georgia, 30328, NDC 24338-856-03 Lots: Lot # F230169A, Exp. 06/30/2025 FDA record D-0323-2024 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Dextroamphetamine RxCUI 3288 4 dose forms · 15 strengths
  1. Dose form (SCDF) Extended Release Oral Capsule RxCUI 371751 In current FDA listings
    Clinical drug / strength (SCD) sulfate 10 MG RxCUI 884520 sulfate 15 MG RxCUI 884532 sulfate 5 MG RxCUI 884535
  2. Dose form (SCDF) Oral Solution RxCUI 757335 In current FDA listings
    Clinical drug / strength (SCD) sulfate 1 MG/ML RxCUI 884522

Look up RxCUI 3288 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Dextroamphetamine costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet · Oral 5 mg $0.384 per tablet NDC details & price history
Tablet · Oral 10 mg $0.373 per tablet NDC details & price history
Tablet · Oral 20 mg $7.04 per tablet NDC details & price history
Tablet · Oral 30 mg $7.06–$10.40 per tablet NDC details & price history
Capsule, Extended Release · Oral 10 mg $0.791 per capsule NDC details & price history
Capsule, Extended Release · Oral 15 mg $1.23 per capsule NDC details & price history
Capsule, Extended Release · Oral 5 mg $0.822 per capsule NDC details & price history
Solution · Oral 5 mg/5 mL $1.62 per mL NDC details & price history
Patch, Extended Release · Transdermal 4.5 mg $16.23 each NDC details & price history
Patch, Extended Release · Transdermal 9 mg $16.26 each NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Dextroamphetamine brand names

Dextroamphetamine is sold under 9 brand names in the FDA directory — Dexedrine, Dexampex, DextroStat, Ferndex and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Dexedrine Dexampex DextroStat Ferndex LiquADD Procentra Zenzedi Xelstrym Dexedrine Spansule

Who makes Dextroamphetamine: manufacturers and labelers

17 companies list Dextroamphetamine products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Azurity Pharmaceuticals, Inc., Winder Laboratories LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Bryant Ranch Prepack 10 Azurity Pharmaceuticals, Inc. 7 Winder Laboratories LLC 7 SpecGx LLC 5 Wilshire Pharmaceuticals, Inc. 5 Noven Therapeutics, LLC 4 Actavis Pharma, Inc. 3 Amneal Pharmaceuticals LLC 3 Amneal Pharmaceuticals of New York LLC 3 Cranbury Pharmaceuticals, LLC 3 Aurolife Pharma, LLC 2 KVK-Tech, Inc. 2 Lupin Pharmaceuticals,Inc. 2 Sunrise Pharmaceutical, Inc. 2 Teva Pharmaceuticals USA, Inc. 2 Independence Pharmaceuticals, Llc 1 Prasco Laboratories 1

Dextroamphetamine drug class (RxNorm)

Dextroamphetamine belongs to the Central Nervous System Stimulant class.

Pharmacologic class Central Nervous System Stimulant
Drug family (ATC) Centrally acting sympathomimetics

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Dextroamphetamine page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective May 19, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Dextroamphetamine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Dextroamphetamine after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
27
Finished products in the current FDA directory
62
Companies listing them (makers, repackagers, distributors)
17
FDA labeler codes behind them ⓘ
18
Linked representative label ⓘ
Tris Pharma Inc
Linked label effective
May 19, 2025
Composite sections available
23
Linked SPL Set ID
7658071e-ee2c-4d23-94ce-1906959ec036
Linked SPL Document ID
442f3920-82b4-41ab-b485-24954a2ebddb
Open the linked representative label on DailyMed ↗
NDC package records associated with this linked SPL 1

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Tris Pharma Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →